Sobi at Morgan Stanley healthcare conference: growth outlook brightens

Sobi raised 2026 revenue guidance to high-teens growth from mid-teens and lifted earnings guidance to the mid-to-high 30% range after Q2 revenue grew 29% and H1 growth reached 26%. Strategic growth products now comprise roughly two-thirds of sales, supporting management's SEK 55 billion ($5.6-$5.7 billion) 2030 revenue target; the hemophilia A franchise is already running above SEK 8 billion annually. Near-term risks include tougher second-half Gamifant comparisons and a manufacturing-related CRL that delays the NASP gout launch until a potential 2027 approval, but management maintained that underlying portfolio momentum remains strong.

Analysis

SOBI’s investable change is not the guidance increase itself but the mix shift: growth increasingly comes from products with multi-year launch curves rather than legacy rare-disease assets. ALTUVOCT’s competitive-switch rate makes it a direct share-loss issue for Roche (ROG.SW) and Sanofi (SAN.PA), while remaining geographic whitespace should support revenue growth beyond the initial launch cohort. The key valuation question is whether investors capitalize the upgraded margin as structural; part of the uplift is plainly deferred launch spending, so 2027 EBITDA conversion—not 2026 guidance—will determine whether the multiple rerates.

The largest embedded optionality, Gamifant in sepsis, should receive essentially no near-term valuation credit. A small, biomarker-defined Phase II signal must survive an adaptive 1,800-2,000-patient program, and endpoint definition, enrollment heterogeneity and FDA alignment create a 2-4 year binary path. Conversely, the near-term risk is more prosaic: difficult H2 comparisons and the manufacturing remediation process can turn a growth deceleration into a credibility issue within the next two quarterly prints.

Aspaveli execution provides a more immediate read-through for BIIB, which owns the asset economics outside Sobi’s territory. Strong European patient starts may improve confidence in complement-franchise demand, but reimbursement and patient-referral friction mean prescription momentum can lag reported sales. Tryngolza is strategically attractive but should be discounted until the second Phase III dataset, payer access and launch economics establish whether a rare-disease commercial platform can scale efficiently into broader lipidology.

Contrarian view: the market may be underestimating operating complexity rather than product potential. Sobi is simultaneously broadening into gout, lipidology and larger trials while undergoing CEO succession; this raises commercial fixed costs and execution risk before new franchises contribute. A clean October regulatory interaction is necessary but insufficient—investors need a documented remediation timeline and 2027 launch-date confidence before assigning meaningful value to the gout franchise.

Key Decisions for Investors

• Initiate a starter long SOBI position over the next 1-3 months, adding only after the October FDA Type A meeting and Q3 evidence that core-product growth offsets Gamifant comparison pressure. Target a 15-20% rerating if 2027 consensus revenue rises on sustained ALTUVOCT/Aspaveli uptake; reduce if management cuts 2027 margin expectations or cannot provide a credible NASP resubmission timeline.
• Pair long SOBI / short ROG.SW or SAN.PA only after hemophilia market-share data confirm continued competitor switching. The thesis is relative franchise erosion rather than a material near-term earnings hit to either mega-cap; use a 6-12 month horizon and exit if switching normalizes in wave-two markets.
• Maintain BIIB on a watch list rather than buying on this read-through. APLS-derived complement economics are relevant, but verify European C3G patient enrollment, net pricing and persistence through the next two quarters; absent those data, the Sobi commentary is not sufficient to change a BIIB earnings model.
• Do not underwrite Gamifant sepsis or the gout pipeline in base-case SOBI valuation. Treat adaptive-trial design/FDA alignment and the NASP manufacturing remediation as catalyst alerts; a failed or delayed regulatory path would likely remove a meaningful portion of pipeline optionality and expose the temporary nature of current margin expansion.